LinkedIn founder Reid Hoffman and Siddhartha Mukherjee, most cancers researcher and creator of the e-book “The Emperor of All Maladies,” have co-founded an AI-powered drug discovery startup, Manas AI. The firm, which is able to initially deal with breast most cancers, prostate most cancers, and lymphoma, has raised $24.6 million in seed funding from Hoffman, General Catalyst, and Greylock.
Manas AI’s capital haul pales in contrast with another startups attempting to make use of AI fashions to develop novel medication. Last 12 months, Xaira, which claimed that it was prepared to start out growing medication, launched with a large $1 billion in preliminary funding. Treeline Biosciences is one other firm that makes use of AI for drug discovery and raised $422 million final 12 months, Endpts reported.
Manas AI claims it should design molecules with AI, then take a look at them in a moist lab, Hoffman reportedly stated through the presentation of his new e-book “Superagency.” Manas says it should use Microsoft’s cloud computing platform, Microsoft Azure, and Microsoft’s “deep area data in AI” to develop novel medicines.
Hoffman has shut ties to Microsoft, which famously acquired his earlier firm, LinkedIn, in a blockbuster deal in 2016.
